Vivek Subbiah: Pleased to share the work of our amazing RET precision medicine team as we review

Vivek Subbiah shared on LinkedIn:

“Hot off the press!

Pleased to share the work of our amazing RET precision medicine team as we review ‘Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers’ published in Cell Reports Medicine, a Cell Press Journal.

Recommendations are provided on the basis of expertise of our group in caring and managing > 100 patients with RET-altered cancers treated with selective RET inhibitors thyroid, NSCLC, and all solid tumors TissueAgnostic + literature review.

Such an honor to work together with fellows+ Advance practice provider+ Pharmacy team and multidisciplinary faculty colleagues on this review.”

Read further.
Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.